J 2025

Targeting proteostasis in multiple myeloma through inhibition of LTK

VATSVEEN, Thea Kristin; Mariaserena GILIBERTO; Valgerdur BJORNSDOTTIR; Federica CENTONZE; Andrej BEŠŠE et. al.

Basic information

Original name

Targeting proteostasis in multiple myeloma through inhibition of LTK

Authors

VATSVEEN, Thea Kristin; Mariaserena GILIBERTO; Valgerdur BJORNSDOTTIR; Federica CENTONZE; Andrej BEŠŠE; Yannick FREY; Sigrid S SKANLAND; Anders TVEITA; Amin ALIREZAYLAVASANI; John Franklin IMBERY; Kristine MISUND; Veronika REITERER; Muhammad ZAHOOR; Christoph DRIESSEN; Lenka BEŠŠE; Kjetil TASKEN; Fredrik H SCHJESVOLD; Hesso FARHAN and Ludvig A MUNTHE

Edition

Leukemia, London, Nature Publishing Group, 2025, 0887-6924

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

is not subject to a state or trade secret

References:

Organization

Lékařská fakulta – Repository – Repository

UT WoS

001527724200001

EID Scopus

2-s2.0-105010413889

Keywords in English

multiple myeloma; LTK kinase; proteostasis; ALK inhibitors; immunoglobulin secretion

Links

LX22NPO5102, research and development project.
Changed: 21/11/2025 00:50, RNDr. Daniel Jakubík

Abstract

In the original language

Multiple myeloma (MM) cells secrete high levels of immunoglobulin and are therefore addicted to mechanisms that maintain proteome homeostasis (proteostasis). While proteasome inhibitors that target the degradative aspect of proteostasis have proven effective, only limited attempts have been made to target protein secretion. Here we show that the receptor tyrosine kinase LTK is a regulatory node in the proteostasis network that responds to secretory load and helps cells maintain a high secretory output. LTK is a highly similar paralog to ALK and by repurposing existing ALK inhibitors, we demonstrate that targeting LTK causes immunoglobulin retention, ER stress and subsequent apoptosis of primary MM cells, even in patients refractory to proteasome inhibitors. Thus, LTK is a novel therapeutic target in the biosynthetic pathway of proteostasis, with significant potential for MM treatment.

Files attached